Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
---|---|---|---|---|---|
Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) | PAR-24-095 | NINDS | (Reissue PAR-21-056) The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal… More | ||
Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | PAR-23-025 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | ||
Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | PAR-23-026 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | ||
Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed) | RFA-OD-23-001 | ORIP | This FOA encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such… More | ||
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | PAR-23-264 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as… More | ||
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) | PAR-23-168 | NIMH | The objective of this funding opportunity announcement (FOA) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment… More | ||
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-23-313 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "… More | ||
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | PAR-23-314 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "… More | ||
Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) | PAR-24-038 | NIDCR | The objective of this Notice of Funding Opportunity (NOFO) is to solicit applications to conduct institutional climate assessments using validated survey instruments and to develop action plans for… More | ||
Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | RFA-DA-24-007 | NIDA | oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of… More |